5-aminosalicylate(5-ASA)agents remain the mainstay treatment in ulcerative colitis(UC).A number of oral 5-ASA agents are commercially available,including azobond pro-drugs,as well as delayed-and controlledrelease form...5-aminosalicylate(5-ASA)agents remain the mainstay treatment in ulcerative colitis(UC).A number of oral 5-ASA agents are commercially available,including azobond pro-drugs,as well as delayed-and controlledrelease forms of mesalazine.However,poor adherence due to frequent daily dosing and a large number of tablets has been shown to be an important barrier to successful management of patients with UC.Recently, new,once-daily formulations of mesalazine,including the unique multi-matrix delivery system and mesalazine granules,were proven to be efficacious in inducing and maintaining remission in mild-to-moderate UC,with a good safety profile comparable to that of other oral mesalazine formulations.In addition,they offer the advantage of a low pill burden and might contribute to increased long-term compliance and treatment success in clinical practice.This editorial summarizes the available literature on the short-and medium-term efficacy and safety of the new once-daily mesalazine formulations.展开更多
Objective: To observe the therapeutic effects of peridural injection of Mailuoning Compound Liquor (脉络宁复合液) for prolapse of lumbar intervertebral disc (PLID). Methods: Peridural injection of Mailuoning Compound ...Objective: To observe the therapeutic effects of peridural injection of Mailuoning Compound Liquor (脉络宁复合液) for prolapse of lumbar intervertebral disc (PLID). Methods: Peridural injection of Mailuoning Compound Liquor (MCL) was given to 100 cases of PLID, once a week, 4 sessions constituting a therapeutic course. By adopting the scoring method, observations were carried out on the total therapeutic effect and changes in the 13 items of the symptoms and signs. Results: After treatment, the JOA scores in this series of patients were markedly enhanced as compared with the scores before treatment, showing significant differences in the paired t test (P<0.05). The sum of the excellent and good rates was 64%, and the total effective rate was 97%. All the scores in the 13 items under observation were significantly raised as compared with the scores before treatment (P<0.05). Conclusion: Peridural injection of MCL is an effective and safe therapy for PLID, and with shorter treating course, quicker therapeutic effects, and less suffering for the patients.展开更多
文摘5-aminosalicylate(5-ASA)agents remain the mainstay treatment in ulcerative colitis(UC).A number of oral 5-ASA agents are commercially available,including azobond pro-drugs,as well as delayed-and controlledrelease forms of mesalazine.However,poor adherence due to frequent daily dosing and a large number of tablets has been shown to be an important barrier to successful management of patients with UC.Recently, new,once-daily formulations of mesalazine,including the unique multi-matrix delivery system and mesalazine granules,were proven to be efficacious in inducing and maintaining remission in mild-to-moderate UC,with a good safety profile comparable to that of other oral mesalazine formulations.In addition,they offer the advantage of a low pill burden and might contribute to increased long-term compliance and treatment success in clinical practice.This editorial summarizes the available literature on the short-and medium-term efficacy and safety of the new once-daily mesalazine formulations.
文摘Objective: To observe the therapeutic effects of peridural injection of Mailuoning Compound Liquor (脉络宁复合液) for prolapse of lumbar intervertebral disc (PLID). Methods: Peridural injection of Mailuoning Compound Liquor (MCL) was given to 100 cases of PLID, once a week, 4 sessions constituting a therapeutic course. By adopting the scoring method, observations were carried out on the total therapeutic effect and changes in the 13 items of the symptoms and signs. Results: After treatment, the JOA scores in this series of patients were markedly enhanced as compared with the scores before treatment, showing significant differences in the paired t test (P<0.05). The sum of the excellent and good rates was 64%, and the total effective rate was 97%. All the scores in the 13 items under observation were significantly raised as compared with the scores before treatment (P<0.05). Conclusion: Peridural injection of MCL is an effective and safe therapy for PLID, and with shorter treating course, quicker therapeutic effects, and less suffering for the patients.
